Abstract
Coronavirus disease 2019 (COVID-19) vaccines, developed using both conventional (inactivated, protein subunit) and novel (messenger RNA, viral vector) platforms, have demonstrated strong effectiveness in preventing severe COVID-19 outcomes and have enabled large-scale characterization of vaccine-induced immunity. To summarize current evidence on the impact of COVID-19 vaccines on the human immune system, emphasizing innate immune activation, adaptive (humoral and cellular) responses, immunological memory and boosting, effects in special populations, and immune-related safety considerations. Across platforms, vaccination triggers a rapid, self-limited innate response mediated by pattern recognition receptor sensing and transient induction of interferons and inflammatory cytokines that supports antigen presentation and lymphocyte priming. Adaptive immunity is characterized by neutralizing anti-spike antibodies and robust T-cell responses, with antibody titers peaking weeks after vaccination and declining thereafter, while memory B-cells and long-lived plasma cells support durable recall responses and improved breadth after boosters. Vaccine-elicited T-cell immunity is relatively durable and less affected by spike variation, contributing to sustained protection against severe disease. Booster doses enhance antibody affinity and breadth and are particularly beneficial in older adults and immunocompromised individuals, who may exhibit attenuated primary responses. Immunologically mediated adverse events are rare, and population-level surveillance shows no evidence of long-term immune suppression attributable to vaccination. COVID-19 vaccines induce controlled innate activation and durable, complementary humoral and cellular immunity, establishing immunological memory that can be strengthened by boosting. These immunological principles support rational booster strategies and inform next-generation vaccine development.